[
  {
    "ts": null,
    "headline": "Biotech Is Booming, and This Undervalued REIT Stands to Gain",
    "summary": "While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences.  Global biotech spending is projected to triple from roughly $1.7 trillion in 2025 to more than $5 trillion by 2034.  All that R&D cash needs purpose‑built laboratory space.",
    "url": "https://finnhub.io/api/news?id=69f44bc81dd3d18f79ecbbcdcc74636a38f005712eb2495255fea43e8607b837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753479360,
      "headline": "Biotech Is Booming, and This Undervalued REIT Stands to Gain",
      "id": 136095093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences.  Global biotech spending is projected to triple from roughly $1.7 trillion in 2025 to more than $5 trillion by 2034.  All that R&D cash needs purpose‑built laboratory space.",
      "url": "https://finnhub.io/api/news?id=69f44bc81dd3d18f79ecbbcdcc74636a38f005712eb2495255fea43e8607b837"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 27",
    "summary": "A weekly summary of payment activity for Dividend Champions, Contenders, and Challengers. Read which stocks have dividend payments coming up, and which ones have changed their dividends.",
    "url": "https://finnhub.io/api/news?id=95f5320a58767cc1c31722d667e3eab996f90c33a0cfe96c809e8633abcaa1b6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753467542,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 27",
      "id": 136092039,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of payment activity for Dividend Champions, Contenders, and Challengers. Read which stocks have dividend payments coming up, and which ones have changed their dividends.",
      "url": "https://finnhub.io/api/news?id=95f5320a58767cc1c31722d667e3eab996f90c33a0cfe96c809e8633abcaa1b6"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9df97e8ac9439370267b1ec4c904e219aeee6102906e5ad2681f10c6cd755e4d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753461600,
      "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "id": 136137052,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9df97e8ac9439370267b1ec4c904e219aeee6102906e5ad2681f10c6cd755e4d"
    }
  },
  {
    "ts": null,
    "headline": "Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia",
    "summary": "The myeloproliferative disorder treatment market is projected to expand at a CAGR of 4.91% from 2025 to 2032, driven by rising prevalence, aging populations, and advancements in molecular diagnostics and targeted therapies. With North America poised for market dominance and key players like Novartis and Bristol Myers Squibb leading the charge, the industry is set for robust growth, offering significant opportunities for innovation and investment.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Mye",
    "url": "https://finnhub.io/api/news?id=518c2d2b2177aab2d1ed47a10f1399cc0a9754ab6436e28a01cd9f38cb3eb8e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753456140,
      "headline": "Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia",
      "id": 136088800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The myeloproliferative disorder treatment market is projected to expand at a CAGR of 4.91% from 2025 to 2032, driven by rising prevalence, aging populations, and advancements in molecular diagnostics and targeted therapies. With North America poised for market dominance and key players like Novartis and Bristol Myers Squibb leading the charge, the industry is set for robust growth, offering significant opportunities for innovation and investment.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"Mye",
      "url": "https://finnhub.io/api/news?id=518c2d2b2177aab2d1ed47a10f1399cc0a9754ab6436e28a01cd9f38cb3eb8e0"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC",
    "summary": "Earnings preview of key companies reporting in the coming week and what to look out for.",
    "url": "https://finnhub.io/api/news?id=675d305c685a59b79d1453c7382d6ed52d84d8edd73e7259243df69108a0ab3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753454192,
      "headline": "Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC",
      "id": 136088416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting in the coming week and what to look out for.",
      "url": "https://finnhub.io/api/news?id=675d305c685a59b79d1453c7382d6ed52d84d8edd73e7259243df69108a0ab3c"
    }
  },
  {
    "ts": null,
    "headline": "Cytokinetics Merits A Speculative Buy Rating",
    "summary": "Cytokinetics stock garners strong analyst support with high growth potential. Here's why the biopharmaceutical's pipeline looks promising this year and beyond.",
    "url": "https://finnhub.io/api/news?id=14a75f3b08438d9637179903cf37cbaae8a4e85039aeb774e7d399bff09f8c93",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753449810,
      "headline": "Cytokinetics Merits A Speculative Buy Rating",
      "id": 136089686,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289907650/image_1289907650.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Cytokinetics stock garners strong analyst support with high growth potential. Here's why the biopharmaceutical's pipeline looks promising this year and beyond.",
      "url": "https://finnhub.io/api/news?id=14a75f3b08438d9637179903cf37cbaae8a4e85039aeb774e7d399bff09f8c93"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers shuffles its executive ranks with new CMO",
    "summary": "AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit Hirawat, on Aug. 1.",
    "url": "https://finnhub.io/api/news?id=8c9792a78662baa826578e48fe0f5d3f645839842dbc75ec9fa5b64a89527667",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753443360,
      "headline": "Bristol Myers shuffles its executive ranks with new CMO",
      "id": 136088802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit Hirawat, on Aug. 1.",
      "url": "https://finnhub.io/api/news?id=8c9792a78662baa826578e48fe0f5d3f645839842dbc75ec9fa5b64a89527667"
    }
  },
  {
    "ts": null,
    "headline": "Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development",
    "summary": "PRINCETON, N.J., July 25, 2025--Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development",
    "url": "https://finnhub.io/api/news?id=bed57553f833a0f3fdb2528e370a6ed478108228bd6b89b1382cce8feb3694d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753441140,
      "headline": "Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development",
      "id": 136085204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., July 25, 2025--Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development",
      "url": "https://finnhub.io/api/news?id=bed57553f833a0f3fdb2528e370a6ed478108228bd6b89b1382cce8feb3694d3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs",
    "summary": "Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs",
    "url": "https://finnhub.io/api/news?id=8a2e7548524e41939477bbde5ed8008215f90dedb99a4f59cadca01a7312771c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753428600,
      "headline": "Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs",
      "id": 136137053,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs",
      "url": "https://finnhub.io/api/news?id=8a2e7548524e41939477bbde5ed8008215f90dedb99a4f59cadca01a7312771c"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finnhub.io/api/news?id=9a1551d4e5e7057de583381407662c1ff1618624444d22f64a99fb4244782763",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753418145,
      "headline": "2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky",
      "id": 136088803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
      "url": "https://finnhub.io/api/news?id=9a1551d4e5e7057de583381407662c1ff1618624444d22f64a99fb4244782763"
    }
  }
]